September 2023 - Page 3 of 4 - BioMedWire (BMW)

ThursdaySep 14, 2023 9:45 am

Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference

Longeveron management will present at the 25th Annual H.C. Wainwright Global Investment Conference scheduled for September 11-13, 2023, in New York Wa’el Hashad, the company’s CEO, will discuss Longeveron’s cellular therapy programs in a pre-recorded presentation. Both he and Lisa Locklear, EVP & Chief Financial Officer, will be at the conference to discuss the company’s investment strategies and clinical trial progress The company aims to create awareness among scientists and investors of its clinical trial progress, positive clinical results, and cellular therapy programs Longeveron is evaluating its lead investigational product candidate, a cellular product named Lomecel-B(TM), in ongoing clinical trials…

ThursdaySep 14, 2023 9:00 am

Leadership Changes At SOHM, Inc. (SHMN) to Strengthen Growth Strategies for Generic Drug Market and Gene Editing Platform Development

U.S.-based generic drug developer SOHM recently announced the addition of two leading officers — Dr. David Aguilar (Ph.D) as Chief Operating Officer and Dr. Krishna Bhat (MD, Ph.D, FACC) as Chief Medical Advisor The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins SOHM also recently announced an LOI to acquire a stem cell disruptive technology and related patents, which include the potential for someday treating damaged hearts via…

ThursdaySep 14, 2023 9:00 am

Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments

Brigham and Women’s Hospital scientists have developed a microdevice to help researchers test the effectiveness of glioma treatments. Gliomas are a type of brain tumor that arise from glial cells in the spinal cord and brain before infiltrating surrounding brain cells. Because the proximity of gliomas to healthy brain cells makes them hard to remove via surgery, glioma treatment often involves removing as much of the tumor via surgery before using chemotherapy or radiation therapy to kill off as many of the remaining cancer cells as possible. Furthermore, researchers find it extremely difficult to test the effects of different drug…

WednesdaySep 13, 2023 1:01 pm

Why Food Allergy Prevalence Is Growing

The director of population health research at the Northwest University’s Center for Food Allergy and Asthma Research suggests that increasing food allergy rates in the developed world may be partly due to advancements in medicine and certain parental habits. By the 1980s, Northwest University Professor Christopher Warren says, the United States had mostly eliminated tapeworms and hookworms. Without any actual threats to deal with, our immune systems downgraded their attention to relatively harmless allergens such as birch pollen and walnuts. Anecdotal results from some researchers who injected themselves with hookworms found that introducing the parasite into their systems somewhat distracted…

WednesdaySep 13, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024 The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD PaxMedica submitted PAX-101 Clinical Trial Request to the South African Health Products Regulatory Authority, requesting approval for a double-blind, placebo-controlled study in ASD The company entered a Research Collaboration Agreement with PoloMar Health and The BRAIN Foundation for a Phase II proof-of-concept trial in ASD PaxMedica (NASDAQ:…

TuesdaySep 12, 2023 10:20 am

Stack Foundation Gives UC San Diego $5M Gift to Advance Gene Therapy

The Stack Foundation has gifted $5 million to the University of California San Diego (UC San Diego) to facilitate gene therapy research for the development of new treatments for genetic disorders in adults and children. UC San Diego said in a recent statement it would launch a Gene Therapy Initiative to meet the need for safer and more effective therapies. Genetic diseases affect fewer than 200,000 people in the United States and can be incredibly hard to treat, especially in the case of rare genetic disorders that have fewer patients to study for the development of effective therapies. Thanks to…

TuesdaySep 12, 2023 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating psoriasis, may offer significant advantages over Apogee Therapeutics, whose recent IPO has resulted in a $1 billion market cap Scinai’s NanoAbs offer additional routes of administration, a higher affinity and binding to the target, and…

MondaySep 11, 2023 2:47 pm

Study Shares Insights on Why Brain Tumors Are Unresponsive to Immunotherapy

University of California Los Angeles (UCLA) scientists have published research findings that could provide deeper insight into why some types of brain tumors respond to immunotherapy while others don’t. While many types of brain tumors typically respond to immunotherapy, an aggressive type of brain cancer called glioblastoma is quite difficult to treat even with immunotherapy. Immunotherapy is a type of cancer treatment that essentially trains the immune system to identify and kill cancer cells, making them more effective at destroying tumors. Glioblastomas start growing from cells in the spinal cord or brain called astrocytes and quickly invade the rest of…

MondaySep 11, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027 RVL Pharmaceuticals (NASDAQ:…

FridaySep 08, 2023 12:43 pm

Being Clear on Value Proposition Key to eCommerce Success

E-commerce companies have a greater chance of succeeding in an increasingly competitive and cutthroat market when they are clear on value proposition. Consumer retail surged during the coronavirus pandemic as nearly a hundred countries instituted self-isolation orders and locked down one-half the global population, forcing countless consumers to rely solely on online stores for their purchases. Convenience was the key drawing factor for most consumers and remains a big factor in the attractiveness of online commerce. According to a Catalyst/Kantar study, 66% of consumers used convenience as their main criteria for choosing online stores while 57% valued shoppability, 52% used…